🚀 VC round data is live in beta, check it out!
InnoCare Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for InnoCare Pharma and similar public comparables like Peptron, Crinetics Pharmaceuticals, Bayer SA, Shijiazhuang Yiling and more.
InnoCare Pharma Overview
About InnoCare Pharma
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
Founded
2015
HQ
Employees
1.1K
Website
Sectors
Financials (LTM)
EV
$3B
InnoCare Pharma Financials
InnoCare Pharma reported last 12-month revenue of $344M and EBITDA of $63M.
In the same LTM period, InnoCare Pharma generated $313M in gross profit, $63M in EBITDA, and $71M in net income.
Revenue (LTM)
InnoCare Pharma P&L
In the most recent fiscal year, InnoCare Pharma reported revenue of $148M and EBITDA of ($46M).
InnoCare Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $344M | XXX | $148M | XXX | XXX | XXX |
| Gross Profit | $313M | XXX | $128M | XXX | XXX | XXX |
| Gross Margin | 91% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | $63M | XXX | ($46M) | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | (31%) | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | (52%) | XXX | XXX | XXX |
| Net Profit | $71M | XXX | ($65M) | XXX | XXX | XXX |
| Net Margin | 21% | XXX | (44%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
InnoCare Pharma Stock Performance
InnoCare Pharma has current market cap of $4B, and enterprise value of $3B.
Market Cap Evolution
InnoCare Pharma's stock price is $2.39.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $4B | -0.8% | XXX | XXX | XXX | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialInnoCare Pharma Valuation Multiples
InnoCare Pharma trades at 9.7x EV/Revenue multiple, and 52.8x EV/EBITDA.
EV / Revenue (LTM)
InnoCare Pharma Financial Valuation Multiples
As of April 18, 2026, InnoCare Pharma has market cap of $4B and EV of $3B.
Equity research analysts estimate InnoCare Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
InnoCare Pharma has a P/E ratio of 59.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 9.7x | XXX | 22.5x | XXX | XXX | XXX |
| EV/EBITDA | 52.8x | XXX | (72.7x) | XXX | XXX | XXX |
| EV/EBIT | 58.3x | XXX | (43.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 10.6x | XXX | 26.1x | XXX | XXX | XXX |
| P/E | 59.3x | XXX | (65.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (51.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified InnoCare Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
InnoCare Pharma Margins & Growth Rates
InnoCare Pharma's revenue in the last 12 month grew by 6%.
InnoCare Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
InnoCare Pharma's rule of 40 is 4% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
InnoCare Pharma's rule of X is 3% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
InnoCare Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 132% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | (31%) | XXX | XXX | XXX |
| EBITDA Growth | (78%) | XXX | (284%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 4% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 3% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 26% | XXX | 26% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 29% | XXX | 5% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 81% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 138% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
InnoCare Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| InnoCare Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Peptron | XXX | XXX | XXX | XXX | XXX | XXX |
| Crinetics Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Bayer SA | XXX | XXX | XXX | XXX | XXX | XXX |
| Shijiazhuang Yiling | XXX | XXX | XXX | XXX | XXX | XXX |
| China Medical System | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
InnoCare Pharma M&A Activity
InnoCare Pharma acquired XXX companies to date.
Last acquisition by InnoCare Pharma was on XXXXXXXX, XXXXX. InnoCare Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by InnoCare Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialInnoCare Pharma Investment Activity
InnoCare Pharma invested in XXX companies to date.
InnoCare Pharma made its latest investment on XXXXXXXX, XXXXX. InnoCare Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by InnoCare Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout InnoCare Pharma
| When was InnoCare Pharma founded? | InnoCare Pharma was founded in 2015. |
| Where is InnoCare Pharma headquartered? | InnoCare Pharma is headquartered in China. |
| How many employees does InnoCare Pharma have? | As of today, InnoCare Pharma has over 1K employees. |
| Who is the CEO of InnoCare Pharma? | InnoCare Pharma's CEO is Jisong Cui. |
| Is InnoCare Pharma publicly listed? | Yes, InnoCare Pharma is a public company listed on HKEX. |
| What is the stock symbol of InnoCare Pharma? | InnoCare Pharma trades under 09969 ticker. |
| When did InnoCare Pharma go public? | InnoCare Pharma went public in 2020. |
| Who are competitors of InnoCare Pharma? | InnoCare Pharma main competitors are Peptron, Crinetics Pharmaceuticals, Bayer SA, Shijiazhuang Yiling. |
| What is the current market cap of InnoCare Pharma? | InnoCare Pharma's current market cap is $4B. |
| What is the current revenue of InnoCare Pharma? | InnoCare Pharma's last 12 months revenue is $344M. |
| What is the current revenue growth of InnoCare Pharma? | InnoCare Pharma revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of InnoCare Pharma? | Current revenue multiple of InnoCare Pharma is 9.7x. |
| Is InnoCare Pharma profitable? | Yes, InnoCare Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of InnoCare Pharma? | InnoCare Pharma's last 12 months EBITDA is $63M. |
| What is InnoCare Pharma's EBITDA margin? | InnoCare Pharma's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of InnoCare Pharma? | Current EBITDA multiple of InnoCare Pharma is 52.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.